Stockreport

Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation

Jounce Therapeutics, Inc.  (JNCE) 
Last jounce therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com
PDF - Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX-4014 and all discovery p [Read more]